



Characterisation of endogenous Galectin-1 and -9
expression in monocyte and macrophage subsets
under resting and inflammatory conditions.




Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Krautter, F, Recio, C, Hussain, MT, Lezama, DR, Maione, F, Chimen, M & Iqbal, AJ 2020, 'Characterisation of
endogenous Galectin-1 and -9 expression in monocyte and macrophage subsets under resting and
inflammatory conditions.', Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, vol. 130,
110595. https://doi.org/10.1016/j.biopha.2020.110595
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 11. May. 2021
Contents lists available at ScienceDirect
Biomedicine & Pharmacotherapy
journal homepage: www.elsevier.com/locate/biopha
Characterisation of endogenous Galectin-1 and -9 expression in monocyte
and macrophage subsets under resting and inflammatory conditions
Franziska Krauttera,1, Carlota Reciob,1, Mohammed T. Hussaina, Danielle R. Lezamaa,
Francesco Maionec,**, Myriam Chimena, Asif J. Iqbala,c,*
a Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
b Instituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Universidad de Las Palmas de Gran Canaria, Farmacología Molecular y Traslacional -
BIOPharm, Las Palmas de G.C, 35016, Spain
c ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy







A B S T R A C T
Macrophages are key cells in both acute and chronic inflammatory settings. Their activation and function highly
depends on the cytokines, chemokines and adhesion molecules that direct monocytes to infiltrate tissues, dif-
ferentiate into macrophages, and finally lead to the clearance of such inflammatory signals. Galectins,
β‐galactoside‐binding lectins, are differentially expressed by various immune cells, and some members of this
family have been identified as regulators of leukocyte recruitment and activation. Galectin-1 (Gal-1) and ga-
lectin-9 (Gal-9) expression has been described in immune cells, but the specific molecular mechanisms by which
they modulate the inflammatory response in macrophages/monocytes are not completely understood. In this
study we sought to comprehensively characterise the expression profile of endogenous Gal-1 and Gal-9 in dif-
ferent murine and human monocyte/macrophage populations in response to different inflammatory stimuli. All
subsets of murine and human macrophages expressed significant levels of Gal-1 and -9. Interestingly, murine
bone marrow derived macrophages stimulated with M2 (pro-resolution) polarising agents preferentially upre-
gulated Gal-1, while Gal-9 expression was upregulated by M1/pro-inflammatory stimulation. However, we
observed differing results in human monocyte derived macrophages. Collectively, our findings report a differ-
ential expression pattern of endogenous Gal-1 and -9 in macrophage and monocyte subsets in response to a range
of inflammatory stimuli. Future studies will endeavour to elucidate whether the galectins make attractive
therapeutic targets or agents for regulating the inflammatory response.
1. Introduction
The inflammatory response is a physiological process that protects
host tissues from injury and infection. A controlled series of events
culminate in the trafficking of leukocytes from the bloodstream into
tissue; a process fundamental for successful cell-mediated immunity
[1].
Once the initiating stimulus is cleared, removal of leukocyte in-
filtrates and a return to tissue homeostasis is required for termination of
the acute inflammatory response. This active process is known as re-
solution. It is driven by macrophages and includes the removal of
harmful materials produced by neutrophils, clearance of apoptotic
inflammatory cells, and delay of apoptosis [2]. Failure of resolution
triggers an uncontrolled inflammatory response and a persistent in-
filtration of leukocytes into tissue which in turn unleashes a chronic and
pathological inflammation [3]. Numerous important human patholo-
gies including arthritis, asthma and atherosclerosis are a result of a
chronic inflammatory response. Although several inflammatory med-
iators (adhesion molecules, cytokines and chemokines) involved in the
recruitment of leukocytes into tissues have been identified, there is still
much to be discovered. In particular, key processes involved in the
persistence of leukocyte infiltrates, widely observed in chronic in-
flammation, have not been be elucidated [4,5]. In this context, mem-
bers of the galectin (Gal) family have recently been identified as
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immunoregulatory proteins whose actions include both positive and
negative modulation of leukocyte recruitment [6,7].
Galectins are a family of soluble β-galactoside-binding lectins that
display different functions depending on their tissue-specific and sub-
cellular location. In vertebrates, 15 galectins have been identified to
date, and can be found either intracellularly, in the nucleus, cytoplasm
and organelles, or extracellularly [8]. All members of the family share
close sequence homology in their carbohydrate recognition domains
(CRD, of approximately 130 amino acids), but exhibit distinct affinities
for different saccharide ligands. Based on their biochemical structure
they are classified into proto-type (containing one CRD in a monomeric
form such as Gal-5, -7, -10, or in a dimeric form such as Gal-1, -2, -11,
-13 and -14), chimera-type (one CRD and an additional non-lectin do-
main involved in the protein oligomerization as is the case of Gal-3),
and tandem-repeat-type (composed of two CRDs connected by a linker
peptide such as Gal-4, -6, -8, -9 and -12) [9,10]. Once synthesized,
galectins may remain within the intracellular compartment and parti-
cipate in protein-protein interactions to regulate intracellular events
[11,12]. However, most galectins are released through an unconven-
tional route to the extracellular compartment [13]. Once secreted, ga-
lectins bind to β‐galactoside sugars and crosslink cells-surface N-acet-
yllactosamine-enriched glycoconjugates. This leads to the activation of
different signal transduction responses through aggregation of specific
cell-surface glycoreceptors. Each galectin may exert different and con-
trasting functions depending on whether it acts extracellularly or in-
tracellularly [9]. Compelling evidence highlights major roles of ga-
lectins modulating inflammation and immune responses [14,15].
Indeed, expression of galectin proteins has been described in infiltrating
inflammatory cells displaying actions at key stages of the inflammatory
response including mast cells degranulation, platelet activation, cell
adhesion, chemotaxis and T-cell apoptosis induction [14]. Importantly,
they are also known to modulate both leukocyte trafficking into tissue
and also clearance of the resulting inflammatory infiltrate; both pro-
cesses being crucial for the initiation and resolution of inflammation
[9]. Among all the family members, Gal-1, -3 and -9 are highly ex-
pressed in immune cells. Gal-3 has been widely studied as an im-
munoregulatory protein in macrophage biology, however, the expres-
sion pattern and function of endogenous Gal-1 and -9 has not been
completely characterized. Gal-1 is composed by two subunits of 14.5
kDa and it is known to weaken acute inflammatory responses by con-
trolling neutrophil adhesion, function and turnover, and modulating
monocyte and macrophage activation [16,17]. Furthermore, Gal-1
controls T-cell viability, mitigates Th1- and Th17- mediated responses
and leans the balance toward a Th2 cytokine profile [18,19]. Its es-
sential role in the regulation of the inflammatory response has been
shown in experimental models of autoimmunity, allergy and cancer
[20–22]. The majority of published studies relating to Gal-9 focuses on
its role in T cell biology, and largely supports an anti-inflammatory and
protective role for the protein. This is thought to be a result of its ability
to induce apoptosis in Th1 and Th17 cells via T-cell immunoglobulin
mucin domain (Tim)-3 [23]. Published studies have identified a role for
Gal-1 and -9 in regulating immune responses in human and murine
models of disease. However, how these regulations differ with macro-
phage populations under different inflammatory stimuli has not been
explored.
The aim of this study was to characterise the expression profile of
endogenous Gal-1 and -9 in different murine and human macrophage
and monocyte populations under both steady state and inflammatory
conditions, in order to determine their suitability as potential ther-
apeutic targets in inflammatory diseases.
2. Materials and methods
All buffers, cell culture media and other laboratory chemicals were
obtained from Sigma-Aldrich (Gillingham, UK) unless otherwise speci-
fied. Cytokines and chemokines were purchased from Peprotech
(London, UK) and R&D Systems (Abingdon, UK). β-actin and α-tubulin
antibodies were purchased from Cell Signaling Technologies (Danvers,
MA, USA), polyclonal Gal-1 (clone AF1125) and Gal-9 (clone AF2045)
antibodies were purchased from R&D Systems. Polyclonal inducible
nitric-oxide synthase (iNOS; clone ab3523) and polyclonal anti-argi-
nase 1 (clone ab60176) were purchased from Abcam. HRP-conjugated
secondary antibodies were obtained from BioRad Laboratories (Hemel
Hempstead, UK) and Cell Signaling.
2.1. Animals
All animal studies (isolation of different cell populations) were
conducted with ethical approval from the Sir William Dunn School of
Pathology, University of Oxford Local Ethical Review Committee and in
accordance with the UK Home Office regulations (Guidance on the
Operation of Animals, Scientific Procedures Act, 1986). Male (7–10
weeks) C57BL/6 mice and neonatal C57BL/6 pups were obtained from
the Biomedical Services Unit (Oxford, UK). All mice were housed in a
12 h light/12 h dark cycle unit with free access to food and water. Adult
animals were euthanised via asphyxiation with a rising concentration of
CO2, whereas neonatal mice were sacrificed by decapitation.
2.1.1. Cell culture
2.1.1.1. Murine bone marrow-derived macrophages (BMDMs). BMDMs
were generated as previously described [24]. Briefly, fresh bone
marrow cells from tibiae and femurs of male C57BL/6 mice were
isolated and cultured in Dulbecco’s Modified Eagle’s medium (DMEM)
supplemented with 10 % heat-inactivated fetal bovine serum (FBS), 10
% L929 cell-conditioned media as a source of macrophage colony-
stimulating factor [25], and 1 % penicillin/streptomycin for 6–7 days.
Bone marrow cells were seeded into 8 mL of medium in 100 mm non-
tissue culture treated Petri dishes (ThermoFisher Scientific, UK). On day
prior the experiment, BMDMs were lifted off dish surface by gently
scrapping and were counted and resuspended in FBS free media at the
desired cell concentration.
2.1.1.2. Resident peritoneal macrophages. male C57BL/6 mice were
sacrificed, and peritoneal cavities were lavaged with 10 mL ice-cold
PBS supplemented with 2 mM EDTA. Cells were pelleted by
centrifugation at 300 g for 5 min, resuspended in DMEM 10 % FBS
and plated for 2−4 h to allow macrophages to attach to the plate.
2.1.1.3. Murine microglia. C57BL/6 pups were sacrificed by
decapitation at 1–3 postnatal days, and heads were placed into a
Petri dish for dissection as previously described (10.21769/
BioProtoc.1989). Briefly, meninges were carefully removed from
brains, minced into small pieces, and incubated with trypsin 0.25 %
and DNase I. After tissue digestion, the suspension was filtered and
resuspended in DMEM supplemented with 10 % FBS and 1 % penicillin/
streptomycin and seeded in culture flasks. After 10–12 days in culture,
detached microglia were collected and plated on 6-well culture dishes
[26].
2.2. Human blood samples
Blood was collected from healthy donors with written and verbal
informed consent and approval from the University of Birmingham
Local Ethical Review Committee (ERN_18−0382). An equal proportion
of male and female donors were used with an age range between
22−70.
2.2.1. Cell culture
2.2.1.1. Human monocyte-derived macrophages (hMDMs). Whole blood
was separated, using density gradients Histopaque 1119 and 1077
(Sigma-Aldrich, U.K.), to obtain the peripheral blood mononuclear cell
(PBMC) fraction. Mixed monocytes were isolated from PBMC, using PBS
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without Ca2+ and Mg2+ supplemented with 0.5 % BSA and 2 mM EDTA
at 4 °C, by positive selection for CD14 using anti-CD14 microbeads and
MACS separation columns (Miltenyi Biotec, Germany). The purity of
mixed monocytes was measured and was consistently ≈95 %. Purified
monocytes were cultured at 37 °C in 5 % CO2 in M199 media (Life
Technologies, Paisley, U.K.) containing 10 ng/mL epidermal growth
factor (EGF) (Sigma-Aldrich, Poole, UK) and 10 % autologous human
serum.
2.3. Compounds and treatments
BMDMs, resident peritoneal macrophages and murine microglia
were seeded onto tissue culture plastic in FBS free media and allowed to
adhere overnight at 37 °C, 5 % CO2. To induce “pro-inflammatory”
(M1) or “pro-resolution” (M2) phenotypes, previously established
treatment protocols were followed (26,699,615). Briefly, M1 and M2
phenotypes were generated by treating BMDMs with LPS (100 ng/mL)
and IFNγ (20 ng/mL) or IL-4 (20 ng/mL) respectively. BMDMs were
additionally treated with compounds at the following concentrations:
Flagellin (500 ng/mL), IL-13 (20 ng/mL), Poly I:C (10 μg/mL) and
Zymosan (10 μg/mL). Resident peritoneal macrophages and murine
microglia were treated with either LPS (100 ng/mL) and IFNγ (20 ng/
mL) or IL-4 (20 ng/mL).
hMDMs were supplemented with M199 media containing 10 ng/mL
EGF and 10 % human autologous serum every two days for six days.
Following this, cells were cultured in M199 media containing 10 ng/mL
EGF and 1 % autologous human serum and three culture conditions
were established; i) untreated ii) treatment with LPS (100 ng/mL) and
IFNγ (20 ng/mL) or iii) treatment with IL-4 (20 ng/mL) [27]. Cells were
stimulated for 16 h before lysis and storage at −80 °C until gene and
protein analysis.
Viability assays (CellTiter Glo Viability Reagent and morphological
analysis) for human monocyte derived and murine macrophages were
performed and no increased cell death was observed in any of the po-
larisation conditions (data not shown).
2.4. mRNA expression analysis
Cultured cells were extracted with TRIzol reagent (ThermoFisher
Scientific) and total RNA concentration and purity was determined with
a ND-1000 spectrophotometer (Nano Drop Technologies, Wilmington,
USA). cDNA was synthesized from 700 ng human RNA or 1000 ng
murine RNA using the QuantiTect Reverse Transcription kit (Qiagen,
Manchester, UK) according to the manufacturer’s instructions. Real-
time quantitative PCR was performed using either Taqman or Sybr
Select gene expression master mix (Life Technologies) in the
StepOnePlus™ thermal cycler (Applied Biosystems). Primers were pur-
chased from Thermo Fisher Scientific (Hs00175478_m1 (CD80);
Hs00267207_m1 (MRC1, coding for CD206); Hs00355202_m1
(LGALS1); Hs04190742_mH (LGALS9); Hs01567026_m1 (CD86);
Hs03003631_g1 (18S)) or Qiagen (NM_008495 (Lgals1, coding for
murine Gal-1); NM_001159301 (Lgals9, coding for murine Gal-9)).
Cycle threshold values were determined by the StepOne software and
target gene expression was normalised to housekeeping gene (18 s).
Relative expression results were plotted as mRNA expression divided by
actin expression, and normalised to basal samples when convenient
[28].
2.5. Protein expression analysis
2.5.1. Western blot
cells were lysed by adding RIPA buffer (Sigma-Aldrich) supple-
mented with protease and phosphatase inhibitors (Sigma-Aldrich) fol-
lowed by manual disruption. BCA protein assay kit (ThermoFisher
Scientific) was used to determine protein concentration. Total cell
protein (20−30 mg) was added to 4x Laemmli buffer (250 mM
Tris−HCl, pH 6.8, 8 % SDS, 40 % glycerol, 0.004 % bromophenol blue,
20 % b-mercaptoethanol) and heated at 95 °C for 5−10 min. Samples
were then resolved on SDS-PAGE gels and transferred onto Hybond ECL
nitrocellulose/PVDF membranes (GE Healthcare, Buckinghamshire,
UK). Membranes were blocked with 5 % milk in TBS-T (Tris-buffered
saline, 0.1 % Tween-20, pH 7.6) for 1 h at room temperature and then
incubated with either polyclonal goat anti-Gal-1, goat anti-Gal-9
(1:1000; R&D Systems), rabbit anti-iNOS, goat anti-arginase 1 (1:2000;
Abcam), rabbit anti-β-actin or rabbit anti- tubulin (both 1:1000, Cell
Signaling Technologies) in 5 % BSA/TBS-T overnight at 4 °C. Next,
membranes were incubated with a HRP-conjugated anti-Goat IgG sec-
ondary antibody for 1 h at room temperature. Protein bands were vi-
sualised by incubating the membranes with Amersham ECL prime and
subsequent exposure to X-ray film over a range of exposure times. For
successive antibody incubations using the same membrane bound an-
tibodies were removed with stripping buffer (ThermoFisher Scientific).
2.5.2. ELISA
Measurement of Gal-1 and Gal-9 secreted protein levels in cell su-
pernatants was performed by ELISA assay (R&D Systems) according to
manufacturer´s instructions.
2.5.3. Flow cytometry
PBMCs were isolated from whole blood, using density gradients as
described above. Cells were either processed directly or washed with
PBS without Ca2+ and Mg2+, PBS containing 25 mM lactose or PBS
containing 25 mM sucrose for 20 min at room temperature with occa-
sional mixing. Cells were incubated with FcR blocking agents (Miltenyi)
in PBS without Ca2+ and Mg2+ containing lactose or sucrose in the
appropriate experiment before staining cells with antibodies against
monocyte subset markers CD14 (TexasRed, clone TuK4, Thermo Fisher)
and CD16 (BV421, clone 3G8, Biolegend, San Diego, USA) as well as
against surface Gal-1 (PE, polyclonal antimouse, R&D Systems) and -9
(BV421, clone 9M1–3, eBioscience, San Diego, USA). Cells were fixed
using 2 % PFA. Intracellular staining was performed using eBioscience
Foxp3/ Transcription Factor Staining Buffer set (ThermoFisher
Scientific) according to the manufacturer’s instructions. Briefly, cells
were stained extracellularly with monocyte subset markers and fixed as
described above. The cells were permeabilised using 1x
Permeabilization Buffer before incubating cells with Gal-1 and Gal-9
antibodies (details above). Unbound antibodies were removed by
washing in 1x Permeabilization Buffer. Protein expression was analysed
by flow cytometry on a Dako CyAn (Beckman Coulter, High Wycombe,
U.K.), and data were analysed using Summit software (Dako). The un-
specific binding of Ab was quantified by using corresponding isotype
controls.
2.5.4. Immunohistochemistry
CD14+ monocytes were isolated from PBMCs as described above. 3
× 105 cells were cultured per well in an ibidi μ-slide 8 well dish (ibidi,
Germany) for 16 h as described above. For extracellular staining the
cells were fixed in 2 % PFA, followed by repeated washing in PBS or
PBS containing 25 mM lactose. Cells for intracellular staining were
fixed with ice cold methanol and repeatedly washed in PBS afterwards.
The cells were blocked using 1 % BSA and 10 % donkey serum in PBS
before incubating the cells with the primary antibody for 1 h at room
temperature. Antibodies used were polyclonal anti-Gal-1 and -Gal9
antibodies (both R&D). Cells were washed repeatedly in PBS before the
Alexa Fluor 488 donkey anti-Goat IgG (H + L) antibody (Invitrogen)
was applied for 1 h at room temperature in the dark. The cells were
washed repeatedly after the incubation. DAPI staining was applied just
before imaging the cells using the Zeiss LSM780 confocal microscope
(Zeiss, Germany). All buffers for the intracellular staining contained 1
% Tween-20 (Sigma-Aldrich). Monocytes, both permeabilized and non-
permeabiliyed, were also stained with the secondary antibody in the
absence of the primary to measure the extent of non-specific binding.
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2.6. Statistical analysis
All quantitative data are expressed as mean± SEM of n in-
dependent biological replicates. Normally distributed data was ana-
lysed using ANOVA followed by multiple comparison using Bonferroni
post-test. Skewed data was analysed using Kruskal-Wallis and Dunn’s
Multiple Comparison tests (Prism 7 GraphPad Software, San Diego, CA,
USA). A P value of< 0.05 was taken to be statistically significant.
3.1. Primary murine M1 and M2 macrophages differentially express Gal-1
and -9
To confirm the expression of Gal-1 and -9 in different murine
macrophage populations, we began by polarising macrophages into
either an “M1-like” pro-inflammatory using LPS + IFNγ or “M2-like”
pro-resolution phenotype using IL-4. In order to validate polarisation
we measured the expression of inducible nitric oxide-synthase (iNOS;
M1 marker) and Arginase 1 (Arg1; M2 marker) by western blot (Fig. 1
A).
Gal-1 mRNA remained unchanged following challenge by LPS and
IFNγ in both microglia and resident peritoneal macrophage (Fig. 1 B,
C). However, Lgals1 mRNA expression was upregulated in both, mi-
croglia and peritoneal macrophages following IL-4 stimulation (Fig. 1
B, C). Lgals9 mRNA expression in resident peritoneal macrophages and
microglia was unchanged following IL-4 treatment but significantly
increased with LPS and IFNγ stimulation when compared to basal
conditions (Fig.1 D and E). To further characterise macrophage galectin
expression, BMDMs were challenged with a range of inflammatory
stimuli including several pathogen-associated molecular patterns
(PAMPs) and selected cytokines. As previously noted, addition of IL-4
trended towards increased expression of Lgals1 mRNA. However, LPS
with or without IFNγ caused a significant reduction in Lgals1 mRNA
expression (Fig. 1 F). Western blot analysis showed that protein levels
remained unaffected across all treatment groups (Fig. 1 G). Interest-
ingly, conditioned culture medium from BMDM supernatants contained
significantly increased levels of Gal-1 upon IL-4 stimulation (Fig.1 H).
Conversely, LPS with or without IFNγ, Poly I:C and zymosan were all
potent inducers of both Lgals9 mRNA and protein expression compared
to non-stimulated (basal) conditions (Fig. 1 I, J).
These results suggest that Gal-1 is upregulated in a M2 macrophages
whilst upregulation of Gal-9 is associated with an M1 Phenotype.
3.2. All human peripheral monocyte subsets have large intracellular pools of
Gal-1 and 9
Peripheral blood mononuclear cells were isolated from whole blood.
CD14 and CD16 were used to identify classical (CL), intermediate (ITM)
and non-classical (NC) monocytes (Fig. 2 A). The flow cytometric
analysis showed that all subsets express Gal-1 and Gal-9 on the surface
(Fig. 2 B–E). A trend for the enrichment of Gal-1 on the surface of CL
and ITM monocytes and Gal-9 on the surface of ITM and NC monocytes
was shown (Fig.2 D, E). However, a substantial difference in en-
dogenous expression of Gal-1 and -9 was observed between donors
(Fig. 2 F, G).
Intracellular pools were detected in both freshly isolated and
cultured monocytes, as seen by flow cytometry and confocal micro-
scopy imaging (Fig. 2 D, E, H).
3.3. Gal-1 is eluted from the cell surface using lactose
Surface expression of Gal-1 and -9 on monocyte subsets was further
investigated using competitive binding assays with β-lactose. Surface
Gal-1 was eluted following β-lactose treatment; however, total Gal-1
levels remained unaffected (Fig. 3 A–C). Irrespective of the presence of
β-lactose, total and surface Gal-9 levels remained unchanged (Fig. 3
D–F). Confocal imaging confirmed that despite β-lactose treatment,
levels of surface Gal-9 remained unchanged while Gal-1 was efficiently
eluted (Fig. 3 G).
3.4. Endogenous Gal-1 and -9 expression in human macrophage subsets
remains stable in response to stimulation
To investigate Gal-1 and -9 profiles in M1- or M2-like phenotypes,
hMDMs were polarised using LPS and IFNγ or IL-4, respectively.
Successful M1 polarisation was confirmed by increased CD80 and CD86
and reduced CD206 mRNA after treatment with LPS and IFNγ.
Conversely, M2 polarisation was corroborated by increased CD206
mRNA levels and reduced CD80 and CD86 expression following treat-
ment with IL-4 (Fig. 4 A–C). Gal-1 expression trended to increase upon
differentiation into M1 but not M2 macrophages at the mRNA (Fig. 4 D)
and protein (Fig. 4 E) level. However, unlike in murine macrophages,
we observed no increase in Gal-1 release by both subsets of macro-
phages (Fig. 4 F). The pattern of Gal-9 expression in human M1 and M2-
like macrophages at mRNA (Fig. 4 G), protein (Fig. 4 H) and secreted
(Fig. 4 I) levels were similar to that of Gal-1.
4. Discussion
Gal-1 and -9 are two members of the galectin family which have
been previously reported to be expressed by immune cells [29]. How-
ever, potential roles for Gal-1 and -9 in modulating the inflammatory
response mediated by macrophages have not been fully explored. In this
study, we demonstrated that Gal-1 is up-regulated in murine M2-like
macrophages whereas Gal-9 increased in M1-like macrophages.
Changes in expression levels of Gal-1 and -9 in M1 vs M2 macrophages
held true at both, mRNA and protein level. Interestingly, we also report
that the pattern of expression for Gal-1 and -9 differs between mice and
humans; stimulation of human monocyte derived macrophages
(hMDM) yielded no significant difference in the expression of either
Gal-1 or -9.
Our findings that Gal-1 is in increased in murine pro-resolving, M2,
macrophages are in line with current reports which characterise Gal-1
as having broadly pro-resolving properties. It is known that the pro-
resolving effects of Gal-1 include the induction of IL-10 production in
activated T-cells and promotion of T-cell anergy in the tumour micro-
environment [30]. Additionally, Gal-1 has been observed to induce IL-
10 production in CD40 stimulated B-cells [31]. It may be possible that
the polarisation of macrophages into a M2 phenotype during resolution
is a means of initiating anti-inflammatory processes via Gal-1 expres-
sion, In contrast however, short-term stimulation of BMDM with LPS
Fig. 1. Gal-1 and -9 mRNA and protein levels in murine BMDM, microglia and peritoneal macrophages. Macrophages were polarised towards M1 or M2
phenotypes treating BMDM using LPS + IFNγ or IL-4 respectively. A Representative Western Blot analysis of arginase I and inducible nitric oxide-synthase in either
untreated, M1 or M2 polarised BMDMs. B-E Murine microglia (B, D) and peritoneal macrophages (C, E) were harvested from C57BL/6 mice. B, C IL-4 treatment
increases Lgals1 mRNA levels compared to basal levels in microglia and peritoneal macrophages. D, E LPS and IFNγ upregulate Lgals9 mRNA levels compared to
basal levels in microglia and peritoneal macrophages. Data acquired via qRT-PCR (F, I), Western blot (G, J) and ELISA (H) using BMDM treated with various
stimulations over 24 h. F qRT-PCR shows varying Lgals1 mRNA expression in BMDM after different treatments for 24 h. G Relative expression of Gal-1 protein in
BMDM after treatment with various stimulations for 24 h alongside a representative Western Blot. H Gal-1 in supernatant of stimulated BMDMs. I qRT-PCR shows
Lgals9 mRNA expression in BMDM is increased after treatment with LPS with and without IFNγ and Zymosan for 24 h J. Relative expression levels of Gal-9 protein in
BMDM after treatment with various stimulations for 24 h alongside a representative Western Blot. Data are expressed as mean± SEM (n = 2-6). Statistical analysis
was conducted using One Way ANOVA/Kruskal-Wallis test*: p = 0.05, **: p = 0.01, ***: p = 0.005, ****: p = 0.001.
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has previously been reported to induce increased expression of Gal-9 in
a TIM-3 dependent manner [32]. Similarly, we have shown that Gal-9
expression increased in murine pro-inflammatory, M1, macrophages in
responses to pro-inflammatory stimuli (Fig.1 D, E). These findings
corroborate reports whereby addition of exogenous Gal-9 promote in-
flammation. For example, the injection of exogenous Gal-9 into mouse
knee joint has been reported to drive arthritogenicity by the increased
infiltration of monocytes into the joint [33]. Mice deficient in
Fig. 2. Total and surface staining for Gal-1 and -9 on human primary monocyte subsets. The monocyte subsets were distinguished by using CD14 and CD16
surface markers. Classical (CL), intermediate (ITM) and non-classical (NC) monocytes were characterised as CD14++CD16−, CD14+CD16+ and CD14−CD16++
cells respectively. A Representative dot-plots of the gating strategy employed in order to distinguish between the CL, ITM and NC monocyte subsets displaying CD16+
events along the Y-axis and CD14+ events along the X-axis. B, C Representative histograms of fluorescence intensities of fluorophore-conjugated antibodies against
Gal-1 and Gal-9 respectively on mixed monocytes. D, E Bar graph of MFIs of total and extracellular Gal-1 and -9 respectively on monocyte subsets (n = 8). F, G
Representative histograms of fluorescent intensities of Gal-1 and Gal-9 on mixed monocytes of individual donors. H Representative images of fluorescently labelled,
intracellular Gal-1 and -9 of cultured CD14+ monocytes imaged using confocal microscopy. Data are expressed as mean± SEM (n = 8).
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Fig. 3. Total and surface staining for Gal-1 and -9 on human primary monocytes washed with β-lactose. A Representative histograms of fluorescent intensities
of fluorophore-conjugated antibodies against extracellular Gal-1 on mixed monocytes. B, C MFI of surface and total Gal-1 on monocyte subsets respectively after
elution with lactose and controls. D Representative histograms of fluorescent intensities of fluorophore-conjugated antibodies against extracellular Gal-9 on mixed
monocytes. E, F Bar graphs of MFI of surface and total Gal-9 respectively of untreated monocyte subsets and monocyte subsets washed with lactose or sucrose. G
Cultured CD14+ monocytes were washed with lactose and stained with Gal-1 and -9 antibodies before imaging with a confocal microscope. The nuclei were stained
with DAPI. Data are expressed as±mean (n = 8). Statistical analysis was conducted using 2-Way ANOVA with Bonferroni post-test. *: p = 0.05, **: p = 0.01, ***: p
= 0.005.
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endogenous Gal-9 have also been shown to have attenuated pathology
in models of lung inflammation and addition of exogenous Gal-9 to
wildtype mice with endotoxic shock has been reported to increase the
incidence of mortality [34]. However, contrasting findings have been
reported on the roles of both Gal-1 and -9 in the context of immune
regulation. Both can be described as pro- or anti-inflammatory,
Fig. 4. Human macrophages increase Gal-1 and Gal-9 expression after treatment with LPS and IFNγ. Macrophages were derived from primary human CD14+
monocytes and stimulated with LPS and IFNγ or IL-4 over 16 h. A-C Macrophage phenotype markers were detected after the stimulation with LPS and IFNγ or IL-4 to
confirm successful polarisation. qRT-PCR was used to detected CD80 and CD86 levels to confirm the polarisation towards M1 macrophages. CD206 mRNA levels were
investigated to confirm polarisation towards M2 macrophages. D, G LGALS1 and LGALS9 mRNA levels of macrophages were quantified using qRT-PCR after 16 h of
treatment with LPS and IFNγ or IL-4. E, H Western blot was used to analyse total Gal-1 and -9 levels of macrophages treated with LPS and IFNγ or IL-4. F, I Gal-1 and
-9 released by stimulated macrophages was detected using ELISA. Data are expressed as mean± SEM (n = 5-9). Statistical analysis was conducted using Kruskal-
Wallis test * p = 0.05 **p = 0.01 *** p = 0.005 **** p = 0.001.
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ultimately this depends on the primary cell types, cellular niche or
environment. For example, the addition of exogenous Gal-1 to os-
teoarthritic chondrocytes has been shown to upregulate a pro-in-
flammatory gene profile [35]. However, the lack of endogenous Gal-1,
in Gal-1 deficient mice, was clinically beneficial in models of experi-
mental arthritis [36]. Therefore, further study is required to understand
the kinetics of Gal-1 and -9 expression in macrophage subsets during
inflammation and resolution and how this may direct the outcomes of
pre-clinical models of inflammation.
In this study, we found that unstimulated human monocytes, iso-
lated from healthy whole blood, express both Gal-1 and -9. Despite
surface expression of both proteins on all three major monocyte subsets,
CL, ITM and NC, each subset also had relatively large intracellular pools
of both Gal -1 and -9 (Fig. 2 B–E). This observation was expected, as
similar patterns of expression have been previously reported in other
cell types, such as endothelial cells and T-cells [37,38]. The importance
of surface versus intracellular expression has been well documented as
the different cellular localizations of galectins can have different, and
sometimes opposing, functions [39]. Galectins are reported to shuttle
between the cytoplasm and the nucleus, and specifically Gal -1 has been
shown to be involved in pre-mRNA splicing events. The addition of
exogenous Gal -9 into cultures of human synovial fibroblasts was shown
to have pro-apoptotic effects; in contrast, endogenous Gal-9 within
these synovial fibroblasts suppressed apoptosis [40]. In the context of
human monocytes specifically, Matsuura et al. showed that in-
tracellular Gal-9 is responsible for the activation of pro-inflammatory
genes in THP-1 cells; a human monocyte cell-line [41]. Interestingly,
overexpression of intracellular Gal-9 induced the expression of pro-in-
flammatory genes, whereas, the addition of exogenous Gal-9 had no
impact on pro-inflammatory genes [41]. Similarly, Ma et al. showed
that the association of intracellular Gal-9 with TIM-3 induced a pro-
inflammatory phenotype in the presence of toll-like receptor (TLR)
stimulation, in THP-1 monocytes/ macrophages. It was observed that
intracellular ligation of Gal-9 with TIM-3 prompted the secretion of IL-
12/ IL-23 in a STAT-3 dependent manner [42]. Further characterisation
of intracellular versus surface galectins and their relative functions in
polarised primary macrophages still requires thorough investigation.
Interestingly, we have seen that the surface of CL and ITM monocytes
trend towards an increase in Gal-1 levels when compared to NC
monocytes (Fig. 2 D). In contrast, NC and ITM monocytes trend towards
a greater enrichment of surface Gal-9 compared to CL monocytes (Fig. 2
E). Further studies are needed in order to determine whether the dif-
ferential expression of galectins amongst monocyte subsets impacts
their function.
We also observed high variations in Gal-1 and -9 expression in
human monocytes and macrophages between donors which did not
coincide with gender or age (Fig. 2 F, G). Further studies are required to
determine the possible causes for these variations, such as lifestyle.
Furthermore, culturing hMDMs in autologous serum may also give rise
to variations due to differences in M-CSF levels in serum amongst do-
nors [43].
Previous studies, using mast cells for example, have shown that
treatment with exogenous Gal-9 can be competitively inhibited with β-
lactose [44]. The elution of endogenous galectin from immune cells has
not been widely published. Here we showed that surface levels of Gal-1
were bound to monocytes in a glycan dependent manner as the protein
was eluted following treatment with β-lactose (Fig. 3 A, B). However,
changes in surface Gal-1 following β-lactose elution were diminutive in
the context of the total cellular pool of Gal-1 (Fig. 3 C). Symons et al.
have previously reported a rapid glycan-dependent dissociation of Gal-
1, after approximately 10 h, from lymphocytic CD45 [45]. A possible
explanation for presence of glycan bound Gal-1 on the surface of
monocytes is its potential role in homeostatic regulation of monocyte
physiology. Barrionuevo et al. have demonstrated that the binding of
exogenous Gal-1 to monocytes is essential for the regulation of con-
stitutive MHC II and FcγRI expression [46]. Additionally, sugar
dependent binding of Gal-1 to its ligands has been previously shown to
be regulated dynamically [10]. Alterations to the redox state of Gal-1
has been proposed to disable its sugar binding capabilities and the
presence of glycan-bound Gal-1 on unstimulated monocytes may re-
present a mechanism for the rapid release of Gal-1 under inflammatory
and oxidative conditions [47]. However, further experiments need to be
conducted in order to determine the true origin of the Gal-1 on the
surface of the primary monocytes.
Interestingly, we observed that Gal-9 was not eluted from the sur-
face of monocytes in the presence of β-lactose and therefore the protein
is presented on the cell surface in a glycan-independent manner (Fig. 3
D, E). Earlier studies have suggested both, glycan-dependent and -in-
dependent binding of Gal-9 to its binding partners on the cell surface.
PDI, a Gal-9 ligand, has been previously reported to primarily bind the
protein in a glycan dependent manner and less so through protein-
protein interactions [48]. The dependency of Gal-9-glycan interactions
holds true for a number of Gal-9 ligands, such as CD44 and CD45 [49].
However, Chabot et al. demonstrated the release of Gal-9 from Jurkat
T-cells was partly dependent on the activity of matrix metalloproteinase
and protein kinase C activity despite Gal-9 itself lacking a signalling
peptide [50,51]. It has been postulated that the release of Gal-9 is
through association with a carrier protein and the inability to elute
surface Gal-9 from monocytes under basal conditions in the current
study may provide greater evidence to this end. Furthermore, Dai et al.
showed that lactose failed to inhibit Gal-9-dependent upregulation of
CD83 and other proteins during dendritic cell maturation [52]. TIM-3
has been shown to be released in association with Gal-9 from PMA
activated THP-1 cells. Even though these previous studies confirm
glycan-independent binding of Gal-9 to cells, further investigation is
required to delineate the mechanistic basis of this binding.
To our surprise, no significant differences in expression of either
LGALS1 and LGALS9 mRNA or Gal-1 and -9 protein were observed, in
hMDM in either LPS + IFNγ or IL-4 treated conditions (Fig. 4 D–I). The
potential difference between mouse and human galectins has been
previously observed in the case of Gal-9. Leitner et al. reported the
potential of the Gal-9 receptor, TIM-3, as a therapeutic target in HIV
associated T-cell exhaustion. In earlier mouse studies, blockade of TIM-
3 was sufficient for restoring exhausted T-cells back to a functional
state. However, they reported that exhausted human T-cells did not
upregulate TIM-3, as murine T-cells do, and the presence of Gal-9
during human T-cell activation did not induce T-cell exhaustion [53].
Similarly, the data presented here may represent genuine variation
between murine and human patterns of expression of various galectin
family members and highlights the importance of caution when making
such interpretations between species.
We have observed no difference in levels of Gal-9 released from
hMDM between treatment groups (Fig. 4 I). However, the current
commercially available ELISA kit for Gal-9 has been reported to mea-
sure degraded Gal-9 in human serum samples and may explain our
observations, especially if the stability of Gal-9 released by differen-
tially stimulated human macrophages may or may not be altered, like
Gal-3 [54]. This is especially pertinent since Gal-9 has been shown to
have altered angiogenic properties and have either pro-apoptotic or
anti-apoptotic effects on TH1 cells when at relatively low or high con-
centrations, respectively [33,55,56].
In summary, our findings support the view that macrophages are
important galectin-expressing cells. However, the results of the current
study highlight that there are differential patterns of expression of Gal-1
and -9 in mice and human. These differences between species must be
taken into consideration when planning experiments, otherwise this
may lead to incorrect conclusions being made. We have observed that
under basal conditions surface levels of Gal-1 are glycan-dependent
while Gal-9 remains glycan independent. However, the surface ex-
pression of both Gal-1 and -9, and any changes in them, were in total
overshadowed by large intracellular pools of both proteins. Further
investigation is required to determine the exact binding and expression
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mechanisms of Gal-1 and -9 on monocytes and how macrophage culture
conditions and polarisation from either CD14+ or CD14- monocytes
influences the relative expression of galectins. Nevertheless, the future
of galectins in the context of macrophage biology looks to be ‘sweet’.
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